Treatment, Symptom Management, and Navigating Antibiotic Resistance
At a Glance
The primary treatment for shigellosis is maintaining hydration with oral rehydration salts. It is critical to avoid anti-diarrheal medications like Imodium, which can trap bacteria and cause severe complications. Antibiotics are reserved for severe cases due to rising drug-resistant strains.
Treating shigellosis is a delicate balance of supporting your body’s natural recovery, managing intense symptoms safely, and carefully selecting medications if the infection becomes severe.
The Foundation of Care: Hydration and Diet
For most individuals, the primary goal of treatment is to replace the fluids and salts lost through diarrhea.
- Oral Rehydration: For mild to moderate cases, Oral Rehydration Salts (ORS) or specialized electrolyte drinks are the standard of care [1]. These are designed with a specific ratio of sugar and salt that helps your intestines absorb water.
- IV Fluids: If you are vomiting and cannot keep liquids down, or if you show signs of severe dehydration, you may require Intravenous (IV) fluids [1].
- Dietary Guidance: While eating might sound unappealing, sticking to a bland diet can help. The BRAT diet (Bananas, Rice, Applesauce, Toast) is gentle on the stomach. Avoid dairy, caffeine, spicy foods, and greasy or high-fat foods, which can further irritate the healing intestinal lining.
Managing Pain and the Anti-Diarrheal Warning
The severe abdominal cramps and tenesmus (constant urge to go) can be exhausting. To manage pain safely, you can use heating pads on your abdomen or over-the-counter pain relievers like acetaminophen (Tylenol). However, there is a critical rule regarding medications:
Do not take anti-motility medications like loperamide (brand name Imodium) [2]. While it may be tempting to try to stop the diarrhea, these drugs work by slowing down the movement of your intestines [3]. In shigellosis, this “traps” the bacteria and their toxins inside your body longer, which can lead to severe inflammation, a dangerously enlarged colon (toxic megacolon), or a life-threatening systemic infection [4].
The Challenge of Antibiotic Resistance
The medical community is currently facing a global crisis with Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Shigella [5][6].
- MDR Shigella: These strains are resistant to at least three different classes of antibiotics [5].
- XDR Shigella: These are even more dangerous “superbugs” that are resistant to all commonly used oral antibiotics, including ciprofloxacin, azithromycin, and ceftriaxone [6][7].
Treatment Decision Guide
Because of this resistance, antibiotic treatment is heavily guided by laboratory testing:
- Mild Symptoms: Hydration and rest. Antibiotics are often avoided to prevent further resistance [1][8].
- Severe or High-Risk Cases: If symptoms are severe, or if the patient is a young child or immunocompromised, doctors may immediately start an “empiric” antibiotic based on local resistance patterns [9]. However, they will simultaneously send a stool culture for an antibiogram (susceptibility test).
- Adjusting Treatment: Once the antibiogram results return (usually in 2-3 days), the doctor will adjust the medication to ensure the bacteria are actually sensitive to the prescribed drug [10][11].
- Highly Resistant Strains: If an XDR strain is detected, the care team may need to use “last-resort” medications like carbapenems, fosfomycin, or tigecycline, which often require specialized care [12][7].
Common questions in this guide
Can I take Imodium to stop the diarrhea from shigellosis?
How is mild shigellosis usually treated?
What does it mean if my Shigella is MDR or XDR?
How can I safely manage the severe stomach cramps?
When should I seek medical attention or IV fluids for shigellosis?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.If my case is severe, what 'empiric' antibiotic are you prescribing while we wait for the stool culture results?
- 2.What over-the-counter pain relievers are safe to take for the cramping?
- 3.If my infection is resistant to common antibiotics, are we prepared to use alternative treatments like ceftriaxone or carbapenems?
- 4.How will we know if the treatment is failing, and at what point would I need to be admitted for IV fluids?
- 5.Are there specific signs of 'toxic megacolon' or other complications I should be monitoring for?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Disparities in Shigellosis Incidence by Census Tract Poverty, Crowding, and Race/Ethnicity in the United States, FoodNet, 2004-2014.
Libby T, Clogher P, Wilson E, et al.
Open forum infectious diseases 2020; (7(2)):ofaa030 doi:10.1093/ofid/ofaa030.
PMID: 32099844 - 2
Risk of Cardiac Lesion with Chronic and Acute Use of Loperamide-An Integrative Review.
Lammoglia BC, Hasselmann G, Pires-Oliveira M, et al.
Journal of cardiovascular development and disease 2022; (9(12)) doi:10.3390/jcdd9120431.
PMID: 36547428 - 3
Radiographic dose-dependency study of loperamide effects on gastrointestinal motor function in the rat. Temporal relationship with nausea-like behavior.
Vera G, Girón R, Martín-Fontelles MI, Abalo R
Neurogastroenterology and motility 2019; (31(8)):e13621 doi:10.1111/nmo.13621.
PMID: 31117152 - 4
Electrocardiographic changes in loperamide toxicity: Case report and review of literature.
Teigeler T, Stahura H, Alimohammad R, et al.
Journal of cardiovascular electrophysiology 2019; (30(11)):2618-2626 doi:10.1111/jce.14129.
PMID: 31432581 - 5
Characterization of genotypes and antimicrobial resistance profiles of clinical isolates of Shigella from patients in the southern region of Iran.
Shoja S, Ghasemi S, Dastranj M, et al.
European journal of medical research 2023; (28(1)):611 doi:10.1186/s40001-023-01570-0.
PMID: 38115112 - 6
Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020-21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri.
Moreno-Mingorance A, Mir-Cros A, Goterris L, et al.
The Journal of antimicrobial chemotherapy 2023; (78(4)):975-982 doi:10.1093/jac/dkad031.
PMID: 36760088 - 7
Cluster of extensively drug-resistant Shigella sonnei carrying blaCTX-M-15 in Los Angeles, California, 2023 to 2024.
Caldera JR, Shaw B, Uslan DZ, Yang S
American journal of infection control 2025; (53(4)):524-526 doi:10.1016/j.ajic.2024.12.005.
PMID: 39667596 - 8
Macrophages orchestrate elimination of Shigella from the intestinal epithelial cell niche via TLR-induced IL-12 and IFN-γ.
Eislmayr KD, Langner C, Liu FL, et al.
bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.01.20.633976.
PMID: 39896533 - 9
Emerging Ceftriaxone Resistance in Paediatric Shigella sonnei: A 10-Year Retrospective Study.
Skripai A, Katz A, Lellouche J, et al.
Acta paediatrica (Oslo, Norway : 1992) 2026; (115(5)):1063-1069 doi:10.1111/apa.70449.
PMID: 41555678 - 10
Antimicrobial resistance in shigellosis: A surveillance study among urban and rural children over 20 years in Bangladesh.
Nuzhat S, Das R, Das S, et al.
PloS one 2022; (17(11)):e0277574 doi:10.1371/journal.pone.0277574.
PMID: 36409683 - 11
Prevalence of Multidrug-Resistant and Extended-Spectrum Beta-Lactamase-Producing Shigella Species in Asia: A Systematic Review and Meta-Analysis.
Salleh MZ, Nik Zuraina NMN, Hajissa K, et al.
Antibiotics (Basel, Switzerland) 2022; (11(11)) doi:10.3390/antibiotics11111653.
PMID: 36421297 - 12
Case of Extensively Drug-Resistant Shigella sonnei Infection, United States.
Choi H, Navarathna DH, Harston BL, et al.
Emerging infectious diseases 2023; (29(8)):1708-1711 doi:10.3201/eid2908.230411.
PMID: 37486233
This page explains shigellosis treatment and antibiotic resistance for educational purposes. Always consult your healthcare provider before taking any medications, especially over-the-counter anti-diarrheal drugs.
Get notified when new evidence is published on Shigellosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.